Azenta Inc. (NASDAQ: AZTA) appointed Trey Martin as president of its multiomics business, effective April 6. Martin will lead the multiomics organization and report to John Marotta, Azenta's president and chief executive officer.

The appointment aims to accelerate execution of Azenta's multiomics long-range plan outlined at its December 2025 investor day. The plan focuses on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated multiomics platform.

Ginger Zhou stepped down from her role as president of the multiomics business and will continue supporting the company in an advisory capacity through November 2026 to ensure continuity during the transition.

Martin most recently served as chief executive officer and board member of Maravai Life Sciences, where he led strategic and operational transformation across a multi-segment life sciences platform. Prior to Maravai, he held senior leadership roles at Danaher Corporation, including senior vice president of genomic medicines and president of Integrated DNA Technologies (IDT).

Martin joined Danaher following their 2018 acquisition of IDT, after helping lead the sale process. He spent more than two decades at IDT in positions of increasing responsibility, helping drive global expansion through organic and inorganic growth investments while sustaining double-digit growth. Martin holds a bachelor's degree in biochemistry from the University of Iowa.

"The business has a strong foundation with deep global expertise and an important role enabling scientists from foundational research to the clinic," Martin said. "I see tremendous opportunities to further differentiate and scale Azenta's unique genomics services and synthesis capabilities to meet the evolving needs of our global customers."

Azenta provides life sciences solutions including cold-chain sample management solutions and multiomics services for drug development, clinical research and advanced cell therapies. The company is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia.